Litcius/Paper detail

FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor

Asher Mullard

2025Nature Reviews Drug Discovery5 citationsDOI

Topics & Concepts

MEK inhibitorGLUEClass (philosophy)MedicinePharmacologyCancer researchInternal medicineOncologyChemistryComputer scienceMaterials scienceMAPK/ERK pathwayKinaseArtificial intelligenceBiochemistryComposite materialCell Adhesion Molecules ResearchMelanoma and MAPK PathwaysPeptidase Inhibition and Analysis
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor | Litcius